High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.
Tissue inhibitor of metalloproteinase-1 (TIMP-1) was evaluated in the pre-treatment serum of 55 newly diagnosed patients with symptomatic myeloma. TIMP-1 was elevated in 47% of patients and correlated with lytic bone disease and increased bone resorption. Importantly, TIMP-1 correlated with ISS stage (p=0.005) and was an independent prognostic covariate for survival [HR: 1.003 (1-1.006), p=0.004] in these patients who were all treated with novel agents (bortezomib and/or IMiDs) during their disease course. Our study provides evidence that pre-treatment serum TIMP-1 is associated with advanced myeloma and suggests the further evaluation of this molecule to better determine its prognostic potential in MM.
Terpos
Evangelos
E
Department of Clinical Therapeutics, University of Athens School of Medicine, 5 Marathonomahon Street, 14572 Drosia, Athens, Greece. eterpos@hotmail.com
Dimopoulos
Meletios A
MA
Shrivastava
Vikas
V
Leitzel
Kim
K
Christoulas
Dimitrios
D
Migkou
Magdalini
M
Gavriatopoulou
Maria
M
Anargyrou
Konstantinos
K
Hamer
Peter
P
Kastritis
Efstathios
E
Carney
Walter
W
Lipton
Allan
A
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D011379:Prognosis; D011719:Pyrazines / Q000627:therapeutic use; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D001897:Boronic Acids; D011719:Pyrazines; D019715:Tissue Inhibitor of Metalloproteinase-1; D000069286:Bortezomib